Results 141 to 150 of about 16,494 (203)
Some of the next articles are maybe not open access.
Naproxen‐probenecid interaction
Clinical Pharmacology & Therapeutics, 1978Probenecid induced major alterations in the half‐life. renal clearance, and metabolism of naproxen. In 6 healthy subjects who received 500‐mg single oral doses of naproxen alone and (following two days of probenecid loading) with 500 mg of probenecid 4 times a day, there was an increase in naproxen plasma half‐life from the normal 14 to 37 hr.
R, Runkel +4 more
openaire +2 more sources
Probenecid-clofibrate interaction
Clinical Pharmacology and Therapeutics, 1981Clofibric acid disposition was studied in four healthy men after 1 wk of clofibrate ingestion (500 mg orally every 12 hr) with and without probenecid (500 mg orally every 6 hr). Mean (+/- SD) free clofibric acid plasma concentration in the four subjects over a dosage interval at steady state was 2.5 +/- 0.03 mg/1 before and 9.05 +/- 1.09 mg/1 after the
J R, Veenendaal +2 more
openaire +2 more sources
Emodin‐induced hepatotoxicity was exacerbated by probenecid through inhibiting UGTs and MRP2
Toxicology and Applied Pharmacology, 2018Aggravating effect of probenecid (a traditional anti‐gout agent) on emodin‐induced hepatotoxicity was evaluated in this study. 33.3% rats died in combination group, while no death was observed in rats treated with emodin alone or probenecid alone ...
Lili Wu +11 more
semanticscholar +1 more source
Journal of Infection, 2019
OBJECTIVES To measure the effect of probenecid, fasting and fed, on flucloxacillin pharmacokinetic and pharmacodynamic endpoints. METHODS Flucloxacillin 1000 mg orally was given to 11 volunteers alone while fasting ('flucloxacillin alone'), and with ...
R. Everts +6 more
semanticscholar +1 more source
OBJECTIVES To measure the effect of probenecid, fasting and fed, on flucloxacillin pharmacokinetic and pharmacodynamic endpoints. METHODS Flucloxacillin 1000 mg orally was given to 11 volunteers alone while fasting ('flucloxacillin alone'), and with ...
R. Everts +6 more
semanticscholar +1 more source
Neuroscience, 2018
Mitochondrial dysfunction and oxidative stress are very prominent and early features in Parkinson's disease (PD) and in animal models of PD. Thus, antioxidant therapy for PD has been proposed, but in clinical trials such strategies have met with very ...
K. Biju +5 more
semanticscholar +1 more source
Mitochondrial dysfunction and oxidative stress are very prominent and early features in Parkinson's disease (PD) and in animal models of PD. Thus, antioxidant therapy for PD has been proposed, but in clinical trials such strategies have met with very ...
K. Biju +5 more
semanticscholar +1 more source
Clinical Pharmacokinetics of Probenecid
Clinical Pharmacokinetics, 1981A review of the clinical applications and of the disposition of probenecid in man, including drug interactions, is presented. Probenecid is the classical competitive inhibitor of organic acid transport in the kidney and other organs. There are 2 primary clinical uses for probenecid: as a uricosuric agent in the treatment of chronic gout and as an ...
R F, Cunningham +2 more
openaire +2 more sources
Journal of Forensic Sciences, 1992
Abstract A death following deliberate ingestion of approximately 75 g of probenecid in a 36-year-old man is described. Tissue concentrations of probenecid were highest in serum (710 mg/L) and liver (550 mg/kg). Probenecid was also detected in vitreous and bile. Ethanol was also detected in blood at 0.13 g/100 mL.
I M, McIntyre +3 more
openaire +2 more sources
Abstract A death following deliberate ingestion of approximately 75 g of probenecid in a 36-year-old man is described. Tissue concentrations of probenecid were highest in serum (710 mg/L) and liver (550 mg/kg). Probenecid was also detected in vitreous and bile. Ethanol was also detected in blood at 0.13 g/100 mL.
I M, McIntyre +3 more
openaire +2 more sources
Probenecid Pharmacokinetics in Cystic Fibrosis
Developmental Pharmacology and Therapeutics, 1991Probenecid pharmacokinetics were studied in 5 cystic fibrosis (CF) subjects and 5 control subjects at oral dosages of 5, 15, and 30 mg/kg. Serum and urine samples were collected for 8 h after administration and assayed by reverse phase high performance liquid chromatography. Pharmacokinetic parameters were estimated by model-independent methods.
A, Weber +4 more
openaire +2 more sources